Abstract
Candida albicans fungus is a microbiota in the human body that is opportunistic. In general, infections caused by C. albicans are called candidiasis. Some studies have shown that C. albicans is resistant to antifungal agents, so an alternative antifungal medication is needed at affordable and safe prices. One alternative is to increase the use of medicinal herbs. The purpose of the research was to study the possibility of utilizing the Temulawak rhizome as a phytopharmaca material to treat candidiasis disease by C. albicans infection. The specific objective is to isolate the bioactive material and to determine the class of antifungal active fraction of Temulawak rhizome against C. albicans. Isolation of temulawak rhizome by way of extracted by stratified using soxhlet, then done fractionation using the method of vacuum chromatography, then bioautographic test using thin plate chromatography. Testing of bioactive fraction temulawak rhizome using thin plate chromatography obtained purple color indicating the class of terpenoids compounds and yellow color indicating the class of phenols compounds. The fraction of methanol extract from Temulawak rhizome makes it possible to be used as raw material of phytopharmaca because it has antifungal effectiveness against C. albicans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
